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 Before squamous cell lung cancer develops, pre-cancerous lesions can be found in 70 
the airways. From longitudinal monitoring, we know that only half of such lesions become 71 
cancer, whereas a third spontaneously regress. While recent studies have described the 72 
presence of an active immune response in high-grade lesions, the mechanisms 73 
underpinning clinical regression of pre-cancerous lesions remain unknown. Here, we show 74 
that host immune surveillance is strongly implicated in lesion regression. Using 75 
bronchoscopic biopsies from human subjects, we find that regressive carcinoma in-situ 76 
lesions harbour more infiltrating immune cells than those that progress to cancer. Moreover, 77 
molecular profiling of these lesions identifies potential immune escape mechanisms 78 
specifically in those that progress to cancer: antigen presentation is impaired by genomic 79 
and epigenetic changes, CCL27/CCR10 signalling is upregulated, and the immunomodulator 80 
TNFSF9 is downregulated. Changes appear intrinsic to the CIS lesions as the adjacent 81 
stroma of progressive and regressive lesions are transcriptomically similar.  82 
 83 
Statement of Significance 84 
Immune evasion is a hallmark of cancer. For the first time, this study identifies mechanisms 85 
by which pre-cancerous lesions evade immune detection during the earliest stages of 86 
carcinogenesis and forms a basis for new therapeutic strategies that treat or prevent early 87 
stage lung cancer. 88 
 89 




 Before the development of lung squamous cell carcinoma (LUSC), pre-invasive lesions 92 
can be observed in the airways. These evolve stepwise, progressing through mild and 93 
moderate dysplasia (low-grade lesions) to severe dysplasia and carcinoma in-situ (CIS; 94 
high-grade lesions), before the development of invasive cancer(1). In cross-sectional 95 
studies, markers of immune sensing and escape have been associated with increasing 96 
grade(2). However, longitudinal bronchoscopic surveillance of such lesions has shown that 97 
progression of pre-invasive lesions to cancer is not inevitable; only half of high-grade CIS 98 
lesions will progress to cancer within two years, whereas a third will spontaneously 99 
regress(3). Our previous work defined the genomic, transcriptomic and epigenetic landscape 100 
of carefully phenotyped airway CIS lesions(4). Here, we combine these data with 101 
immunohistochemistry (IHC), imaging and transcriptomic analysis of adjacent stroma (Table 102 
S1; Figure S1) to assess the role of immune surveillance in lesion regression. We identify 103 
key immune escape mechanisms enriched in pre-invasive lesions which later progressed to 104 
cancer. Understanding these mechanisms may offer new therapeutic strategies to induce 105 
regression and prevent the development of invasive disease. 106 
 107 
Results 108 
To assess our hypothesis that lesion regression is driven by immune surveillance, we 109 
used a deep-learning approach(5) to quantify lymphocytes from hematoxylin and eosin 110 
(H&E) stained slides in a large dataset of 112 samples from 62 patients, which contained 111 
more infiltrating lymphocytes in regressive lesions than progressive (Figure 1a; p=0.049). 112 
We next performed immunohistochemistry (IHC) on 28 progressive and 16 regressive CIS 113 
lesions from 29 patients (Figure 1b-c). Regressive lesions showed higher concentrations of 114 
intra-lesional CD8+ cytotoxic T-cells (Figure 1a; p=0.055) but no significant difference in 115 
CD4+ T helper cells (p=0.26) or FOXP3+ regulatory T cells (p=0.42). We then quantified 116 
immune cells in stromal regions adjacent to CIS lesions, but found no significant differences 117 
between progressive and regressive lesions for CD8+ (p=0.50), CD4+ (p=0.43) or FOXP3+ 118 
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(p=0.64) cells. We confirmed these findings in an independent dataset of 19 progressive and 119 
9 regressive samples subjected to multiplex IHC(6,7) (mIHC) using a wider antibody panel of 120 
lymphoid biomarkers (Table S2), in which we again observed that regressive lesions had an 121 
increased proportion of infiltrating lymphocytes (Figure 2a; p=0.032). Specifically, regressive 122 
lesions showed significantly more infiltrating CD3+CD8+ cytotoxic T-cells (p=0.017) but no 123 
significant difference in CD3+CD4+ T helper cells (p=0.18), T regulatory cells (p=0.12), B-124 
cells (p=0.12), macrophages (p=0.79) or neutrophils (p=0.53). In the mIHC cohort, the 125 
proportion of CD3+CD8+ cells positive for granzyme B and EOMES was similar between 126 
progressive and regressive lesions (p=0.63 and p=0.18 respectively) which may indicate that 127 
disruption of T-cell infiltration into lesions has a greater impact on their capacity for immune 128 
evasion than impairment of cytotoxic function or differentiation. Again, stromal regions in this 129 
cohort showed no significant differences between progressive and regressive lesions. 130 
For a broader assessment of transcriptomic differences between CIS lesions and 131 
their adjacent stroma, we isolated epithelial tissue and paired stroma separately using laser 132 
capture microdissection for 10 progressive and 8 regressive CIS lesions. Similarly to IHC 133 
data, cell type deconvolution analysis using the Danaher method(8) demonstrated higher 134 
infiltrating lymphocytes within regressive lesions (Figure 2b; p=0.0046), as did 135 
deconvolution of methylation data from 36 progressive and 18 regressive CIS lesions using 136 
methylCIBERSORT(9) (Figure 2c; p=0.0081). Comparing predictions for individual cell 137 
types across gene expression and methylation data found an increase in most immune cell 138 
types in regressive lesions compared to progressive (Table S3).  139 
Analysis of cytokines classically considered to be pro- or anti-inflammatory within the 140 
epithelial compartment (Table S4) demonstrated an increase in pro-inflammatory (p=3.7x10-141 
4) but not anti-inflammatory (p=0.32) response in regressive lesions compared to 142 
progressive (Figure S2a-f). IL2, TNF, IL12A and IL23A were all increased in regressive 143 
lesions (Figure S3a-b; FDR=0.0081, FDR=0.00051, FDR=0.00078, FDR=0.011 144 
respectively). Only CXCL8 was upregulated in progressive samples compared to regressive 145 
(FDR=0.0063); produced by macrophages, the expression of CXCL8 correlated strongly with 146 
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macrophage quantification from deconvoluted gene expression data (r2=0.62, p=0.007). 147 
Taken together, these data are in keeping with a model in which inflammation via pathways 148 
including IL-2 and TNF fosters effective immune surveillance, whilst lesion-associated 149 
macrophages – similar to tumor-associated macrophages in advanced cancers – have an 150 
immunosuppressive effect. 151 
Given the well-known immunosuppressive effects of smoking, we hypothesised that 152 
patients who were current smokers were more likely to show reduced immune infiltrate and 153 
therefore a higher chance of progression. Smoking status was available for 132 CIS lesions 154 
from 59 patients (24 lesions from 13 current smokers; 104 from 43 former smokers; 4 from 3 155 
never smokers; Figure S4a-j). Using a Cochrane-Armitage test to look for a trend from 156 
Current to Former to Never smokers, we found a trend towards higher chance of regression 157 
(p=0.002) and more infiltrating lymphocytes (p=0.095). This trend is still observed, yet no 158 
longer statistically significant, using a bootstrapping method to account for samples from the 159 
same patient (p=0.069 for regression; p=0.12 for infiltrating lymphocytes). Interestingly, 160 
within the former-smoker group we did not observe increasing lymphocytes or chance of 161 
regression with increasing time since quitting smoking, suggesting that the observed 162 
differences in outcome are driven by the active process of smoking and its direct effects on 163 
the immune response, rather than by chronic processes of airway remodelling and 164 
repair(10). 165 
Recent advances have demonstrated heterogeneity of lung cancer immune 166 
infiltration, with patients whose tumors have predominantly infiltrated ‘immune hot’ regions 167 
having improved survival as compared to those with abundant poorly infiltrated, ‘immune 168 
cold’ regions(11,12). Hierarchical clustering of immune cell quantification by mIHC and by 169 
deconvolution of both transcriptomic and epigenetic data demonstrated clear clusters of 170 
‘cold’ lesions, almost all of which progressed to cancer (Figure 2d-f). However, we also 171 
observed some ‘hot’ progressive lesions, suggesting the presence of other immune evasion 172 
mechanisms in these lesions. We therefore sought to address two questions: firstly, could 173 
deficits in antigen presentation and immune recruitment in progressive lesions be identified, 174 
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which could explain the observed ‘cold’ lesions? Secondly, could disordered immune cell 175 
function explain the existence of progressive immune ‘hot’ lesions? 176 
The acquisition of mutations that result in clonal neoantigens drives T cell 177 
immunoreactivity in cancer(13). We hypothesised that immune-active regressive lesions 178 
may contain more neoantigens than progressive lesions, however, this was not supported by 179 
whole-genome sequencing data(4) (n=39). Predicted neoantigens correlated very closely 180 
with mutational burden (r2=0.94), and progressive lesions have been shown to have 181 
significantly higher mutational burden than regressive lesions(4), therefore more 182 
neoantigens were identified in progressive than regressive lesions (Figure S5a-b; p=0.088). 183 
This remained true when the analysis was limited to clonal neoantigens (Figure S5c; 184 
p=0.023) and there was no difference in the proportion of neoantigens that were clonal 185 
(Figure S5d; p=0.76). Further, there were no significant differences in binding affinity 186 
(p=0.46) or differential agretopicity index(14)(p=0.58) and the ratio of observed to expected 187 
neoantigens (“depletion score”(15)) was not significantly different (Figure S5e-h; p=0.94), 188 
therefore the putative neoantigens themselves were not qualitatively different in the 189 
regressive group. The increased number of neoantigens identified in progressive lesions 190 
suggests that immune escape mechanisms must be active in these lesions; indeed, these 191 
antigens may act as a selection pressure to promote the development of immune 192 
escape(16). Importantly, no overlap in putative tumor neoantigens was observed between 193 
different patients suggesting that vaccine-based approaches aiming to prevent progression 194 
will most likely need to be designed on a personalised basis. 195 
Given that neoantigens are present in progressive lesions, we assessed the ability of 196 
these lesions to present antigens to the immune system. In cancer, genomic alterations 197 
have previously been associated with modulation of immune response(17,18). We studied 198 
mutations and copy number burden of 62 genes expressed by cancer cells which are 199 
involved in the following pathways: antigen presentation by MHC mechanisms, antigen 200 
processing and immunomodulation (stimulation and inhibition of T-cell responses) (Figure 201 
3). Mutations and CNAs in these genes were more prevalent in progressive than regressive 202 
9 
 
samples (p=0.003). Four of these genes – B2M, CHUK, KDR and CD80 – had a significantly 203 
elevated dN/dS ratio (19) – comparison of the rates of non-synonymous to synonymous 204 
mutations – indicating positive selection for acquisition of mutations in these genes. We 205 
observe that expression of immunostimulatory genes predominantly positively correlates 206 
with infiltrating lymphocytes in CIS, and these genes are mostly downregulated in 207 
progressive compared to regressive CIS. Conversely, inhibitory genes predominantly 208 
correlate negatively with infiltrating lymphocytes and are upregulated in progressive lesions.  209 
Loss of heterozygosity (LOH) in the HLA region, which is found in 61% of LUSC 210 
patients(20), was identified in 34% of patients with CIS lesions. Interestingly, a similar 211 
proportion of LUSC patients (28%) demonstrated clonal HLA LOH(20), suggesting that such 212 
clonal events may often occur prior to tumor invasion; future longitudinal studies will be 213 
required to confirm this. We did not find a statistically significant difference in the prevalence 214 
of HLA LOH between progressive and regressive lesions (p=0.25) although sample numbers 215 
were small. Expression of HLA-A was significantly reduced in progressive compared to 216 
regressive lesions (p=1.9x10-10).  217 
Additionally, hypermethylation of the HLA region, which is well-described in invasive 218 
cancers(21,22), was commonly observed, suggesting that epigenetic HLA silencing may be 219 
an important immune escape mechanism in pre-invasive disease. Genome-wide differential 220 
methylation analysis between progressive and regressive lesions identified differentially 221 
methylated regions (DMRs) including a striking cluster of hypermethylation in chromosome 6 222 
((4); Figure S6a-b), covering a region containing all of the major HLA genes. This cluster 223 
was also identified in analysis of 370 LUSC versus 42 control samples published by the 224 
Cancer Genome Atlas(23). Further analysis of TCGA data demonstrate strong evidence for 225 
epigenetic silencing of multiple genes in the antigen presentation pathway: mean 226 
methylation beta value over the gene is inversely correlated with expression for HLA-A (r2=-227 
0.32, p=2.5x10-10), HLA-B (r2=-0.42, p<2.2x10-16), HLA-C (r2=-0.18, p=3.6x10-4), TAP1 (r2=-228 
0.53, p<2.2x10-16) and B2M (r2=-0.38, p=1.1x10-14). Similar trends were observed in CIS 229 
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data (Figure S7a-b). The methylation pattern affecting these genes is predominantly 230 
promoter hypermethylation (Figure S8). 231 
Demethylating agents have been shown to promote immune activation through 232 
improved antigen presentation, immune migration and T cell activity(24–26). These data 233 
support the case for moving on-going trials of demethylating agents in combination with 234 
immunotherapy from advanced lung cancer into early disease (examples of such trials 235 
include NCT01928576 and NCT03220477, registered at https://clinicaltrials.gov/). 236 
Additionally, several other cancer-associated pathways are known to be affected by 237 
methylation changes(4), therefore the benefits of these drugs may extend beyond immune 238 
activation. Nevertheless, we note with caution that some key immune genes demonstrate 239 
positive correlations in TCGA data between gene expression and methylation, including the 240 
immune co-stimulating ligand TNFSF9 (coding for 4-1BBL) (r2=0.32, p=1.7x10-10) and the 241 
MHC class II transcriptional activator CIITA (r2=0.39, p=2.5x10-15) (Figure S7). Further 242 
studies will be required to demonstrate that immunological benefits of demethylating agents 243 
are not outweighed by effects on these important pathways. 244 
Despite this evidence for impairment of antigen presentation mechanisms in CIS, we 245 
do observe ‘immune hot’ CIS lesions which progress to cancer. We therefore next 246 
considered functional and microenvironment-related mechanisms to explain how these 247 
lesions were able to evade immune predation.  248 
To study microenvironment effects on the immune response, we performed gene 249 
expression profiling on laser-captured stromal tissue taken from regions adjacent to CIS 250 
lesions. In contrast to data from gastrointestinal pre-invasive lesions(27), no genes were 251 
significantly differentially expressed on comparing stromal expression between progressive 252 
(n=10) and regressive (n=8) lesions when a FDR of <0.1 was applied. This result holds true 253 
with restricted hypothesis testing considering only genes that are related to immunity and 254 
inflammation (Figure 4a-b; Table S4). 255 
Targeting immunomodulatory molecules such as PD-1 now forms part of first-line 256 
lung cancer management(28). PD-L1 expression is common in invasive LUSC with 257 
11 
 
estimates of positivity ranging from 34% to 52%, depending on criteria(29). Whilst we did not 258 
identify transcriptional upregulation of the PD-L1 gene (CD274; Figure 4c-d), IHC data 259 
identified 3 samples with >25% of epithelial cells (PanCK+) also positive for PD-L1 (Figure 260 
4e), all of which progressed to cancer, suggesting that targeting this pathway early in the 261 
clinical course may have therapeutic benefit in selected patients.  262 
To investigate the role of immunomodulatory molecules more broadly in pre-invasive 263 
immune escape, we performed differential expression analysis between progressive and 264 
regressive lesions, focused on 28 known immunomodulatory genes (Table S4). TNFSF9 (4-265 
1BBL, CD137L) was significantly downregulated in progressive lesions (FDR=4.34x10-5; 266 
Figure 4c-d) with no corresponding change identified in its receptor TNFRSF9 (FDR=0.6). 267 
These findings were corroborated by IHC (Figure 4e-f). TNFSF9 promotes activation of T 268 
cells and natural killer (NK) cells(30); in CIS lesions TNFSF9 expression correlates with 269 
cytotoxic cell (r2=0.77, p=0.0002) and NK cell infiltration (r2=0.54, p=0.02), as predicted from 270 
gene expression data. Agonists of the TNFSF9 receptor have been shown to be clinically 271 
efficacious in several cancers(31–33) and these data support their investigation in targeted 272 
early lung cancer cohorts. Furthermore, individual lesions showed notably high or low 273 
expression of other immunomodulatory genes, raising the possibility that other 274 
immunomodulators may be targets for therapy in individual cases (Figure S9).  275 
To identify differences in cytokine responses between progressive and regressive 276 
lesions, we calculated the ligand:receptor mRNA expression ratio for 52 known 277 
cytokine:receptor pairs(34). Only one, CCL27:CCR10, was significant with FDR < 0.01 (Fold 278 
change 1.55, FDR 0.003); progressive samples express more CCL27 (p=2.6x10-6) and less 279 
CCR10 (p=0.1x10-4) than regressive (Figure 4c-d). Whilst sample numbers were small, 280 
these findings were broadly supported by IHC (Figure 4e-g). CCL27:CCR10 signaling has 281 
been associated with immune escape in melanoma through PIK/Akt activation in a mouse 282 
model(35); in CIS, CCL27 expression correlates with expression of both PIK3CA (r2=0.61, 283 
p=0.008) and AKT1 (r2=0.68, p=0.002) (Figure S10a-b). CCL27 is minimally expressed in 284 
both normal lung tissue and invasive squamous cell lung cancer(23,36), suggesting that this 285 
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effect is specific to early carcinogenesis and therefore warrants further investigation as a 286 
target for preventative therapy. 287 
Our previous research highlighted occasional cases of ‘late progressive’ lesions, 288 
which met a clinical endpoint of regression (defined by the subsequent biopsy at the same 289 
site showing resolution to normal epithelium or low-grade dysplasia) but the index CIS 290 
biopsy had the molecular appearance of a progressive lesion, and it indeed subsequently 291 
developed cancer months or years later. Clinical review identified 11 lesions across the 53 292 
regressive lesions in our current cohort (20.7%) that at later clinical follow up subsequently 293 
progressed to cancer, and hence are termed ‘late progressive’. These included 4 previously 294 
published lesions subjected to whole-genome sequencing and/or methylation and shown to 295 
display the genomically unstable appearance of progressive lesions, as well as 7 with 296 
immunohistochemistry data and 10 with lymphocyte quantification performed from H&E 297 
slides (Table S1; Figure S1). Interestingly, based on these data, late progressive lesions 298 
appear immunologically similar to regressive lesions, showing increased infiltration with 299 
lymphocytes and CD8+ T-cells compared to progressive lesions (Figure S11).  300 
Whilst we acknowledge that sample numbers are small when examining subgroups 301 
of regressive lesions in this way, our data support a model in which lesions can be 302 
considered on two axes: genomic stability and immune competence. Our previous work 303 
predicts that chromosomally unstable lesions will usually progress, implying that they have 304 
escaped immune predation. Yet some may regress if they remain immune competent only to 305 
later progress, potentially due to their genomic instability making them more likely to evolve 306 
immune escape mechanisms during regression, and hence become ‘late progressors’. Of 11 307 
late progressors in this cohort, median time from regressive index biopsy to progression was 308 
3.2 years (range 0.8-4.6 years). This time period represents a change from a point of known 309 
immune competence to demonstrated immune escape. Hence, we might estimate that a 310 
successful therapeutic strategy to block a particular immune escape mechanism might delay 311 
the onset of cancer by around 3 years. Of the remaining 42 regressive samples in this 312 
cohort, median follow-up time was 4.73 years (range 0.42-13.5 years), suggesting that 313 
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genomically ‘stable’ samples are likely to regress and remain regressed long-term. Given 314 
their immunological competence, late progressors are included in the regressive cohort 315 




 In summary, we present evidence that immune surveillance may play a 320 
critical role in spontaneous regression of pre-cancerous lesions of the airways. Whilst recent 321 
cross-sectional studies have greatly furthered our understanding of immune signals prior to 322 
cancer invasion, and indeed at earlier disease stages than CIS(2,12), we have for the first 323 
time shown an association with lesion regression. Including such outcome data offers insight 324 
into the dynamics of immune surveillance and evasion; assuming that lesion regression is 325 
driven by immune surveillance – which is likely based on our data – we are able to directly 326 
compare preinvasive lesions which are immune competent (regressed) with those that are 327 
able to evade immune predation (progressed). Analysis of ‘late progressive’ samples 328 
furthers this model by providing estimates of timescales over which immune evasion 329 
evolves. Hence we provide a roadmap for manipulation of the immune system as a cancer 330 
intervention strategy, by identifying and targeting differences between these two immune 331 
states. 332 
To this end, we identify mechanisms of immune escape present before the point of 333 
cancer invasion, many of which offer potential therapeutic targets. These data present an 334 
opportunity to induce regression and prevent cancer development. Demethylating agents, 4-335 
1BB agonists and CCL27 blockade are therapeutic candidates that warrant further research, 336 
as well as targeting the PD-1/PD-L1 axis in highly selected patients. As a result of field 337 
carcinogenesis, patients with pre-invasive lesions are at risk of synchronous cancers at 338 
other sites, which are likely to be clonally related(4,37) and therefore may benefit from 339 
systemic immunomodulatory treatment. The data presented here support a new paradigm of 340 
personalised immune-based systemic therapy in early disease. 341 
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Additional methods are provided in a supplementary file accompanying this manuscript. 344 
 345 
Ethical approval 346 
All tissue and bronchial brushing samples were obtained under written informed patient 347 
consent and were fully anonymized. Study approval was provided by the UCL/UCLH Local 348 
Ethics Committee (REC references 06/Q0505/12 and 01/0148). All relevant ethical 349 
regulations were followed. 350 
 351 
Cohort description and patient characteristics 352 
 For over 20 years, patients presenting with pre-invasive lesions, which are 353 
precursors of squamous cell lung cancer (LUSC), have been referred to the UCLH 354 
Surveillance Study. As previously described(3), patients undergo repeat bronchoscopy every 355 
four months, with definitive treatment performed only on detection of invasive cancer. 356 
Autofluorescence bronchoscopy is used to ensure the same anatomical site is biopsied at 357 
each time point. Gene expression, methylation and whole genome sequencing data of 358 
carcinoma in-situ (CIS) samples have been performed on this cohort, and data have been 359 
published(4). These data are used in this study.  360 
 All patients enrolled in the UCLH Surveillance Study who met a clinical end point of 361 
progression or regression were included; by definition they underwent an ‘index’ CIS biopsy 362 
followed by a diagnostic cancer biopsy (progression) or a normal/low-grade biopsy 363 
(regression) four months later. Index lesions were identified between 1999 and 2017. Cases 364 
meeting an end-point of regression underwent clinical review to identify those which 365 
subsequently progressed; 11 samples (20.7%) were identified, which are described as ‘late 366 
progressors’ in the main text. Of these 11, median time from ‘regressive’ index biopsy to 367 
progression was 3.2 years (range 0.8-4.6 years) whilst the remaining 42 samples had a 368 
median follow up time of 4.73 years (range 0.42-13.5 years). Whilst we cannot fully exclude 369 
that any regressive sample may later develop cancer, the fact that median follow up in the 370 
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study group was longer than the maximum follow up in the late progression group suggests 371 
that late progression in included samples is unlikely. 372 
All samples underwent laser capture microdissection (LCM) to ensure only CIS cells 373 
underwent molecular profiling. Methods for sample acquisition, quality control and mutation 374 
calling are as previously described, as are full details regarding patient clinical 375 
characteristics. 376 
 Briefly, gene expression profiling was performed using both Illumina and Affymetrix 377 
microarray platforms. Normalisation was performed using proprietary Illumina software and 378 
the RMA method of the affy(38) Bioconductor package respectively. This study includes 18 379 
previously unpublished gene expression arrays from stromal tissue. These samples were 380 
collected using LCM to identify stromal regions adjacent to 18 already-published CIS 381 
samples (corresponding to the 18 samples undergoing Affymetrix microarray profiling 382 
described above). These new stromal samples underwent Affymetrix profiling using the 383 
exact same methodology as previously described for CIS tissue samples. To avoid issues 384 
related to batch effects between platforms, the analyses in this paper utilise only samples 385 
profiled on Affymetrix microarrays, which include both CIS and matched stromal samples 386 
(see Supplementary Methods and Table S5). 387 
Methylation profiling was performed using the Illumina HumanMethylation450k 388 
microarray platform. All data processing was performed using the ChAMP Bioconductor 389 
package(39). 390 
Whole genome sequencing data was obtained using the Illumina HiSeq X Ten 391 
system. A minimum sequencing depth of 40x was required. BWA-MEM was used to align 392 
data to the human genome (NCBI build 37). Unmapped reads and PCR duplicates were 393 
removed. Substitutions, insertions-deletions, copy number aberrations and structural 394 









Sample selection for profiling 402 
As previously described, all patients enrolled in the surveillance programme discussed 403 
above were considered for this study. For a given CIS lesion under surveillance, when a 404 
biopsy from the same site in the lung showed evidence of progression to invasive cancer or 405 
regression to normal epithelium or low-grade dysplasia, we defined the preceding CIS 406 
biopsy as a progressive or regressive ‘index’ lesion respectively. Due to the small size of 407 
bronchoscopic biopsy samples, not all profiling techniques were applied to all samples. 408 
Patients with Fresh Frozen (FF) samples underwent whole genome sequencing and/or 409 
methylation analysis depending on sample quality. Patients with formalin-fixed paraffin-410 
embedded (FFPE) samples underwent gene expression analysis. Further detail is available 411 
in our previous manuscript(4). Additionally, any patient with an available FFPE block 412 
underwent image analysis as described below, and all patients with Affymetrix-based gene 413 
expression profiling underwent further profiling of laser-captured adjacent stroma. 414 
 415 
 416 
Statistical Methods 417 
Unless otherwise specified, all analyses were performed in an R statistical 418 
environment (v3.5.0; www.r-project.org/) using Bioconductor(45) version 3.7. Code to 419 
reproduce a specific statistical test is publicly available at the Github repository above. 420 
Unless otherwise stated, comparisons of means between two independent groups are 421 
performed using a two-sided Wilcoxon test. In some cases, multiple samples have been 422 
profiled from the same patient, although always from distinct sites within the lung. In such 423 
cases we used mixed effects models to compare means between groups, treating the 424 
patient ID as a random effect, as implemented in the Bioconductor lme4 library(46), with p-425 
values calculated using the Anova method from the Bioconductor car library (available from 426 
18 
 
https://cran.r-project.org/web/packages/car). Differential expression was performed using the 427 
limma(47) Bioconductor package to compare microarray data between two groups. When 428 
adjustment for multiple correction is required we quote a False Discovery Rate (FDR) which 429 
is calculated using the Benjamini-Hochberg method(48). Cluster analysis and visualization 430 
was performed using the pheatmap Bioconductor package (available from https://cran.r-431 
project.org/web/packages/pheatmap/). 432 
 433 
Data Availability 434 
All raw data used in this study is publicly available. Previously published CIS gene 435 
expression and methylation data is stored on GEO under accession number GSE108124; 436 
matched stromal gene expression data is stored under accession number GSE133690. 437 
Previously published CIS whole genome sequencing data is available from the European 438 
Genome Phenome Archive (https://www.ebi.ac.uk/ega/) under accession number 439 
EGAD00001003883. Annotated H&E images of all samples used for lymphocyte 440 
quantification were deposited to the Image Data Resource (https://idr.openmicroscopy.org) 441 
under accession number idr0082. 442 
 443 
Code Availability 444 
All code used in our analysis will be made available at http://github.com/ucl-445 
respiratory/cis_immunology on publication. All software dependencies, full version 446 
information, and parameters used in our analysis can be found here. 447 
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Figure legends 627 
 628 
Figure 1. Immune cell infiltration of lung carcinoma-in-situ lesions. a) Combined 629 
quantitative immunohistochemistry data of CD4, CD8 and FOXP3 staining (n=44; 28 630 
progressive, 16 regressive) with total lymphocyte quantification from H&E images (n=112; 68 631 
progressive, 44 regressive) shown. We observe increased lymphocytes (p=0.049) and CD8+ 632 
cells (p=0.055) per unit area of epithelium within regressive CIS lesions compared to 633 
progressive. Stromal regions adjacent to CIS lesions showed no significant differences in 634 
immune cells between progressive and regressive lesions. p-values are calculated using 635 
linear mixed effects models to account for samples from the same patient; #p<0.1, *p<0.05. 636 
(b-c) Immunohistochemistry images of (b) progressive CIS lesion and (c) regressive CIS 637 
lesion with CD4+ T helper cells stained in brown, CD8+ cytotoxic T-cells in red and FOXP3+ 638 
T regulatory cells in blue. Immune cells are separately quantified within the CIS lesion and in 639 
the surrounding stroma.  640 
 641 
Figure 2. Identification of immune ‘hot’ and ‘cold’ carcinoma in-situ lesions by 642 
immune cell clustering. Regressive lesions harbored significantly more infiltrating 643 
lymphocytes as assessed by multiplex immunohistochemistry (a; p=0.032 comparing 644 
percentage of all nucleated cells identified as T-cells (CD45+CD3+) or B-cells (CD45+CD3-645 
CD20+) between 19 progressive and 9 regressive lesions). This finding was corroborated by 646 
molecular data in partially overlapping datasets; regressive lesions had higher gene-647 
expression derived Tumor Infiltrating Lymphocyte (TIL) scores (b; p=0.0046; n=10 648 
progressive, 8 regressive) and a higher proportion of immune cells as estimated from 649 
methylation data using methylCIBERSORT (c; p=0.0081; n=36 progressive, 18 regressive).  650 
d) Immune cell quantification from IHC data (n=28) shows an ‘immune cold’ cluster (left) in 651 
which most lesions progressed to cancer, and an ‘immune hot’ cluster (right) in which the 652 
majority regressed. Similar clustering patterns are seen in deconvoluted gene expression 653 
data (e; n=18) and on methylation-derived cell subtypes using methylCIBERSORT (f; n=54). 654 
26 
 
p-values are calculated using mixed effects models to account for samples from the same 655 
patient. 656 
  657 
27 
 
Figure 3. Genomic aberrations affecting immune genes in lung carcinoma in-situ 658 
lesions. The mutational status is shown for 62 genes involved in the immune response, 659 
which are expressed by antigen presenting (tumor) cells. Genes are categorized as 660 
belonging to the Major Histocompatibility Complex (MHC) class I or II; stimulators (Stim) and 661 
inhibitors (Inhib) of the immune response, and genes involved in antigen processing (Ag-662 
Proc). Mutations and copy number aberrations (CNAs) are shown for each of 29 progressive 663 
and 10 regressive samples. Loss of heterozygosity (LOH) events are shown as mutations to 664 
avoid confusion with copy number loss, relative to ploidy. The GXN PvR column displays the 665 
fold-change in expression of each gene between progressive and regressive samples, 666 
defined in a partially overlapping set of 18 samples. Significant genes, defined as False 667 
Discovery Rate < 0.05, are highlighted in blue. The TILcor column displays the Pearson's 668 
correlation coefficient between the expression of each gene and the gene-expression based 669 
tumour infiltrating lymphocyte (TIL) score, derived by the Danaher method. Progressive 670 
samples had more mutations (p=0.028) and CNAs (p=0.0038) than regressive in this gene 671 
set. dN/dS analysis identified B2M, CHUK, KDR and CD80 as showing evidence of 672 
selection. 673 
 674 
Figure 4. Immune escape mechanisms in CIS beyond antigen presentation. (a) 675 
Volcano plot of gene expression differential analysis of laser-captured stroma comparing 676 
progressive (n=10) and regressive (n=8) CIS samples. No genes were significant with FDR 677 
< 0.05 following adjustment for multiple testing. (b) Principle component analysis plot of the 678 
same 18 CIS samples, showing laser-captured epithelium and matched stroma. (c-d) RNA 679 
analysis of immunomodulatory molecules and cytokine:receptor pairs in n=18 CIS samples 680 
identified TNFSF9 and CCL27:CCR10 as significantly differentially expressed between 681 
progressive and regressive samples (p=0.0000058 and p=0.0000019 respectively). (e) 682 
Immunohistochemistry showed that TNFSF9 was similarly differentially expressed at the 683 
protein level (p=0.057; n=7 with successful staining). (f) Illustrative immunohistochemistry 684 
staining for TNFSF9. CCL27 and CCR10 showed a similar trend at the protein level to the 685 
28 
 
RNA level (e,g); whilst these data did not achieve a significance threshold (g; p=0.49 for 686 
CCL27:CCR10 ratio, n=10) we observe several outliers in the progressive group. Analysis of 687 
PD-L1 (encoded by CD274) and its receptor PD-1 (encoded by PDCD1) is included due to 688 
its relevance in clinical practice; again we do not achieve statistically significant results but 689 
do observe three marked outliers with PD-L1 expression >25%, all of which progressed to 690 
cancer. All p-values are calculated using linear mixed effects modeling to account for 691 
samples from the same patient; ***p < 0.001 **p < 0.01 *p<0.05 #p<0.1. Units for gene 692 
expression figures represent normalised microarray intensity values.  693 
 694 
 695 
